Antibodies

11 Aug 2021 SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants
10 Aug 2021 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
10 Aug 2021 FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced Endometrial Carcinoma
10 Aug 2021 Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
09 Aug 2021 Phase III Study Shows Genentech's Polivy Plus R-CHP is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
09 Aug 2021 Enhertu significantly improved progression-free survival in DESTINY-Breast03 head-to-head trial vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
06 Aug 2021 Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
06 Aug 2021 Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis (ranibizumab) to the U.S. Food and Drug Administration (FDA)
06 Aug 2021 Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases
05 Aug 2021 CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)
05 Aug 2021 First Patient Dosed in CUPID Study of Telix’s Targeted Alpha Therapy Candidate for Prostate Cancer
05 Aug 2021 Abcentra Announces First Patients Dosed with Orticumab in Clinical Trial Evaluating Blockade of Oxidized LDL in Psoriasis with Elevated Cardiometabolic Risk
05 Aug 2021 Merck’s KEYTRUDA® (pembrolizumab) Significantly Prolonged Recurrence-Free Survival (RFS) Compared to Placebo as Adjuvant Therapy for Patients With Stage II Resected High-Risk Melanoma in Phase 3 KEYNOTE-716 Trial
05 Aug 2021 Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer
04 Aug 2021 Ambrx Announces First Patient Dosed in a Phase 1 Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors
03 Aug 2021 FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
02 Aug 2021 Prometheus Biosciences Announces Initiation of APOLLO-CD Phase 2a Clinical Trial of PRA023 in Moderate-to-Severe Crohn’s Disease
02 Aug 2021 Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
02 Aug 2021 Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers
02 Aug 2021 Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis
02 Aug 2021 Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
31 Jul 2021 FDA Expands Authorized Use of REGEN-COV™ (casirivimab and imdevimab)
31 Jul 2021 Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
30 Jul 2021 Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid Tumors
30 Jul 2021 Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top